Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock jumped on Friday after the FDA issued a new boxed warning for Elevidys. The updated approval follows recent reports of fatal liver injury in non-ambulatory pediatric patients who received the gene therapy. SRPT stock is moving. Watch the price action here. The FDA has updated the labeling for Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), by adding its highest-level safety warning—a Boxed Warning—and restricting its approved use. Read Next: Shk ...